

Case Number:	CM14-0076632		
Date Assigned:	07/18/2014	Date of Injury:	03/19/2010
Decision Date:	10/02/2014	UR Denial Date:	05/12/2014
Priority:	Standard	Application Received:	05/27/2014

HOW THE IMR FINAL DETERMINATION WAS MADE

MAXIMUS Federal Services sent the complete case file to an expert reviewer. He/she has no affiliation with the employer, employee, providers or the claims administrator. The expert reviewer is Board Certified in Occupational Medicine and is licensed to practice in California. He/she has been in active clinical practice for more than five years and is currently working at least 24 hours a week in active practice. The expert reviewer was selected based on his/her clinical experience, education, background, and expertise in the same or similar specialties that evaluate and/or treat the medical condition and disputed items/services. He/she is familiar with governing laws and regulations, including the strength of evidence hierarchy that applies to Independent Medical Review determinations.

CLINICAL CASE SUMMARY

The expert reviewer developed the following clinical case summary based on a review of the case file, including all medical records:

According to the records made available for review, this is a 51-year-old female with a 3/19/10 date of injury. At the time (5/12/14) of the Decision for authorization for Voltaren Gel 1 % between 05/08/2014 and 06/22/2014, there is documentation of subjective (neck and right upper extremity pain) and objective (decreased range of motion in all planes) findings, current diagnoses (Cervical Radiculopathy and Cervical Disc Herniations with Neural foraminal narrowing), and treatment to date (medications including ongoing treatment with Voltaren gel, Tramadol ER, Flexeril, and Gabapentin). The 5/12/14 medical report identifies that the patient has been taking Voltaren gel with significant temporary pain relief. There is no documentation of osteoarthritis pain in joints that lend themselves to topical treatment (ankle, elbow, foot, hand, knee, and wrist); failure of an oral NSAID or contraindications to oral NSAIDs; short-term use (4-12 weeks); and functional benefit or improvement as a reduction in work restrictions; an increase in activity tolerance; and/or a reduction in the use of medications as a result of Voltaren Gel use to date.

IMR ISSUES, DECISIONS AND RATIONALES

The Final Determination was based on decisions for the disputed items/services set forth below:

Voltaren Gel 1 %, QTY: 1 tube, between 05/08/2014 and 06/22/2014: Upheld

Claims Administrator guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Topical Analgesics.

MAXIMUS guideline: Decision based on MTUS Chronic Pain Treatment Guidelines Non-steroidal anti-inflammatory agents (NSAIDs) Page(s): 111-112. Decision based on Non-MTUS Citation Official Disability Guidelines (ODG) Pain, Diclofenac sodium Other Medical Treatment Guideline for Medical Evidence: Title 8, California Code of Regulations, section 9792.20

Decision rationale: MTUS Chronic Pain Medical Treatment Guidelines identifies documentation of osteoarthritis pain in joints that lend themselves to topical treatment (ankle, elbow, foot, hand, knee, and wrist) and short-term use (4-12 weeks), as criteria necessary to support the medical necessity of Voltaren Gel 1%. In addition, MTUS-Definitions identifies that any treatment intervention should not be continued in the absence of functional benefit or improvement as a reduction in work restrictions; an increase in activity tolerance; and/or a reduction in the use of medications or medical services. ODG identifies documentation of failure of an oral NSAID or contraindications to oral NSAIDs, as criteria necessary to support the medical necessity of Voltaren Gel. Within the medical information available for review, there is documentation of diagnoses of Cervical Radiculopathy and Cervical Disc Herniations with Neural foraminal narrowing. In addition, there is documentation of ongoing treatment with Voltaren Gel. However, there is no documentation of osteoarthritis pain in joints that lend themselves to topical treatment (ankle, elbow, foot, hand, knee, and wrist), and failure of an oral NSAID or contraindications to oral NSAIDs. In addition, given documentation of ongoing treatment with Voltaren Gel, there is no (clear) documentation of short-term use (4-12 weeks). Furthermore, despite documentation of significant temporary pain relief, there is no documentation of functional benefit or improvement as a reduction in work restrictions; an increase in activity tolerance; and/or a reduction in the use of medications as a result of Voltaren Gel use to date. Therefore, based on the guidelines and review of the evidence, the request for Voltaren Gel 1 % between 05/08/2014 and 06/22/2014 is not medically necessary.